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Risks of anti-obesity therapies  Introduction 
The epidemic of obesity is now recognized as 
one of the most important public health 
problems facing the world today.  
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Future perspectives 
• BMI index ≥ 25 kg/m2 Overweight 
• BMI index ≥ 30 kg/m2 Obese 
Pharmacological treatment ofobesity aim not only to reduce body weight, but it also to 
prevent health comorbidities. First step of obesity treatment is using non-pharmacologic 
method such as nutrition, physical activity, and behaviour therapy. If the patient does not 
achieve adequate weight loss pharmacotherapy can be considered before applying more 
invasive interventions such as surgical treatment.  
 
Past anti-obesity therapies 
• Promotion of pathways  involved in hunger and calorie 
restriction are related with  longer lifespan 
• Calorie restriction  reduce inflammation and down regulate  
immune responses which improved several risks factors for 
chronic diseases. 
• Resveratrol may act as a calorie restriction mimetic and 
enhanced health indexes, despite not ameliorating obesity.  
Calorie 
restriction 
• Promote pathways involved in the effects of regular exercise to 
improved the health in these subjects 
• Metformin: inductor of AMP-activated protein Kinase (AMPK) 
signalling 
• Irisin: acts in the white adipose tissue to stimulate the 
expression of UCP1 and brown-fat development 
Exercise 
• Target peripheral tissues such as adipose tissue, as a mean to 
avoid undesirable side effects on the central nervous system 
• Inhibitors of methionine aminopeptidase 2 (MetAP2) like  
Fumagilin inhibits angiogenesis in adipose tissue resulting in a 
decrease in fat accumulation 
• Targeting  the brown adipose tissue in order to increase its 
energy expenditure may be also a future approach 
Peripheral 
tissue 
 
The activation of POMC neurons, which 
utilize glucose as a main fuel to promote 
potential actions, promote of satiety, 
which leads to suppression of feeding 
and increases energy expenditure. 
 
On the other hand, NPY/AgRP neurons 
are known to utilize mainly fatty acids to 
promote  potential actions, promote 
satiety which leads to food craving.  
 
The by-products of glucose or fatty 
acids oxidation produce reactive oxygen 
species (ROS) which plays a critical role 
in the promotion of POMC neuronal 
firing.  
Satiety relies on continuous ROS 
production in the hypothalamus and an 
associated glucose-triggered ROS 
production in the periphery. That would 
mean that sustained satiety induced by 
anti-obesity therapies will , by default, 
result in ROS-induced damage in central 
and peripheral tissues.  
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Current anti-obesity therapies 
• Mechanisms underlying metabolism homeostatic energy needs to keep being 
investigate in order to identify new targets and also to have a better 
comprehension of the pathogenesis of obesity  
• Pathway that do not involved in promotion of satiety may offer a solution to the 
development of new anti-obesity drugs with less side effects 
• Meanwhile new anti-obesity drugs are discovered, governments should keep 
invest in obesity prevention 
Figure 2. Timeline indicating  some  of the many  anti-obesity therapies  used in the past that have been retired  from the 
market due to its side effects. Modified from: Trends Neurosci.; 2013;36(2):133–40 
Figure 4. During a positive energy balance, POMC neurons 
are firing actively using glucose as main fuel at the same 
time they increased ROS accumulation in these cells. Thus, 
sustained ROS levels in POMC neurons appear to favour 
satiety. So, glucose-induced ROS generation in POMC 
neurons is actually fundamental to the promotion of 
satiety.  Extracted from: Nat Rev Drug Discov 
2012;11(9):675–91 
 
Figure 3.Mechanims of action of the current anti-obesity therapies on the market. a) Phentermine increase the 
adrenergic tone  that reduces food intake and increases resting energy expenditure. Topiramate induces appetite 
suppression and satiety via a combination of (GABA) mediated inhibitory activity, modulation of voltage-gated calcium 
and sodium channels, kainite glutamate receptors. b) Bupropion stimulated hypothalamic proopiomelanocoritn (POMC) 
neurons that release alpha-melanocyte stimulating hormone (α-MSH) which binds to MC3 and MC4 receptors inhibiting 
food intake and inducing satiety. Naltrexone long-acting opioid receptor antagonist (mainly of µ and ĸ receptors that 
antagonize the effects of β-endorphins c) Inhibition of both pancreatic and gastric lipases required for the hydrolysis of fat  
d) Selective and potent agonist of 5-HT2C that  induce satiety. Modified from : Nat Rev Drug Discov 2012;11(9):675–91 
 
 
Overweight and obesity, are the fifth most 
common risk factors for death. Moreover 
they are predisposing factor to develop other disorders such as dyslipidaemia, 
hypertension or diabetes type 2 and cardiovascular  disease among other. It has also been 
related to some cancer and with physiological problems including depression and low self- 
stem. 
 
Figure 1. The graphic shows 
the increasing prevalence of 
overweight adults in 
industrialized countries.  Spain 
is predicted to have more 
than half of the population 
suffering from overweigh by 
2020.  Figure taken from: 
Foresight.Tackling Obesities: Future 
Choices – Project report (2014) 
Obesity is found in ancient time, and so do medications to treat it. Moreover most of the 
last century  anti-obesity therapies are now withdraw. 
Nowadays there are only four drugs available in the market to treat obesity that have the 
approval of the FDA, whereas in Europe there is only three of them. Moreover, only two of 
those pharmacological treatments are approved for a long- term therapy (Orlistat and 
Lorcaserin) whereas the other two (Phenetermine/topiramate and Naltrexone/Bupropion) 
are only approved for short term management of obesity (≤12 weeks).   
 a) b) 
c) 
d) 
Due to the risks of anti-obesity drugs that promote satiety, investigator are now are 
trying to target other pathways involve in calorie restriction, exercise and also to act on 
peripheral tissue rather that in the central nervous system to avoid side effects of 
nowadays therapies. 
